• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

    75.66 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Mar 10, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,162
    Open 75.66
    Bid (Size) 75.00 (100)
    Ask (Size) 78.00 (500)
    Prev. Close 75.66
    Today's Range 75.66 - 75.66
    52wk Range 23.95 - 86.74
    Shares Outstanding 141,797,854
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Ionis announces changes to Board of Directors
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire

    Performance

    YTD
    -5.0%
    -5.0%
    1 Month
    -10.8%
    -10.8%
    3 Month
    -4.1%
    -4.1%
    6 Month
    +17.5%
    +17.5%
    1 Year
    +134.8%
    +134.8%

    More News

    Read More
    News headline image
    Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG)
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    Ionis Pharmaceuticals (NASDAQ:IONS) Shows High Technical and Setup Ratings for Potential Breakout ↗
    Via Chartmill
    IONIS PHARMACEUTICALS INC (NASDAQ:IONS) Shows High-Quality Technical Breakout Setup ↗
    Via Chartmill
    News headline image
    Ionis to present at upcoming investor conferences
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis updates time for fourth quarter and full year 2025 financial results webcast
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance
    Via Finterra
    Topics Economy Intellectual Property
    News headline image
    Ionis to hold fourth quarter and full year 2025 financial results webcast
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    What a $20 Million Bet on a Stock Down 3% Signals for Investors ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Autoliv Stock Is Up 32% in a Year, But One Fund Just Cut $3.8 Million ↗
    Via The Motley Fool
    Topics Regulatory Compliance Supply Chain
    News headline image
    DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE)
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis to present at 44th Annual J.P. Morgan Healthcare Conference
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    The RNAi Powerhouse: A Deep Dive into Alnylam Pharmaceuticals’ Path to the S&P 500
    Via PredictStreet
    Topics Economy Intellectual Property Stocks
    News headline image
    Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    Biogen Completes Acquisition of Alcyone Therapeutics
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE)
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis Prices Convertible Notes Offering to Refinance 2026 Convertible Notes
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire

    Frequently Asked Questions

    Is Ionis Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, Ionis Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does Ionis Pharmaceuticals, Inc. - Common Stock trade on?
    Ionis Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Ionis Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for Ionis Pharmaceuticals, Inc. - Common Stock is IONS on the Nasdaq Stock Market
    What is the current price of Ionis Pharmaceuticals, Inc. - Common Stock?
    The current price of Ionis Pharmaceuticals, Inc. - Common Stock is 75.66
    When was Ionis Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of Ionis Pharmaceuticals, Inc. - Common Stock was at 03/10/26 04:00 PM ET
    What is the market capitalization of Ionis Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of Ionis Pharmaceuticals, Inc. - Common Stock is 10.73B
    How many shares of Ionis Pharmaceuticals, Inc. - Common Stock are outstanding?
    Ionis Pharmaceuticals, Inc. - Common Stock has 11B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.